 |
|
Van Andel Institute Study Rules Out Transcriptional Coactivators as Useful Herpes Antiviral Drug Targets
March 26, 2009Researchers at Van Andel Research Institute (VARI) have determined that the herpes simplex virus type 1 (HSV-1) does not require transcriptional coactivators for viral gene expression early in the infection process. The finding is significant in determining that, in contradiction to earlier models, chemical inhibitors of these cellular proteins are not likely to serve as useful antiviral drugs.
Researchers sought to determine how herpes simplex virus "turns on" its viral genes during the first stages of infection. Specifically, they tested whether the expression of the viral genes would be similar to how cellular genes are turned on, and specifically whether the viral genes would depend on a set of cellular proteins called "coactivators."
"Based on an earlier model we expected that expression of the viral genes would depend on a set of transcriptional coactivators," said Scientific Investigator Steve Triezenberg, Ph.D., head of the VARI Laboratory of Transcriptional Regulation and co-author of the study published in a recent issue of the Journal of Virology. "As it turns out, we got an unexpected answer. Using several different approaches, we consistently saw that the coactivator proteins are not required for viral gene expression."
Researchers have understood that virion protein 16 (VP16) of herpes simplex virus type 1 is a potent transcriptional activator of viral immediate early (IE) genes. However, the role of transcriptional coactivators had not been fully understood.
"This is a significant finding because it tells us that chemical inhibitors of these coactivators are not likely to be good antiviral drugs, despite our earlier model," said Triezenberg.
Van Andel Institute
Researchers have understood that virion protein 16 (VP16) of herpes simplex virus type 1 is a potent transcriptional activator of viral immediate early (IE) genes. However, the role of transcriptional coactivators had not been fully understood.
"This is a significant finding because it tells us that chemical inhibitors of these coactivators are not likely to be good antiviral drugs, despite our earlier model," said Triezenberg.
Van Andel Institute
Viral Genes Current Events and Viral Genes News RSSResearch uncovers clues to virus-cancer link
In a series of recently-published articles, a research team from the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center has uncovered clues to the development of cancers in AIDS patients.
Researchers engineer pancreatic cell transplants to evade immune response
In a finding that could significantly influence the way type 1 diabetes is treated, researchers at Albert Einstein College of Medicine of Yeshiva University have developed a technique for transplanting insulin-producing pancreatic cells that causes only a minimal immune response in recipients.
Deep sea expedition sets sail
Setting sail on the Pacific, a University of Delaware-led research team has embarked on an extreme adventure that will find several of its members plunging deep into the sea to study hydrothermal vents on the ocean floor.
Vaccine triggers immune response, prevents Alzheimer's
A vaccine created by University of Rochester Medical Center scientists prevents the development of Alzheimer's disease-like pathology in mice without causing inflammation or significant side effects.
The cooperative view: New evidence suggests a symbiogenetic origin for the centrosome
There are two ways in which cooperation is the theme of a paper published this week by Mark Alliegro and Mary Anne Alliegro, scientists at the Marine Biological Laboratory's (MBL) Josephine Bay Paul Center.
Fruit flies show how salmonella escapes immune defenses
Salmonella are wily and obnoxious bacterial invaders--escape artists capable of evading multiple immune responses and causing a harsh and debilitating intestinal infection.
Cell death suppression increases efficacy of M2 vaccines
Significant public attention has recently been focused on the development of new anti-influenza (flu) vaccines that provide protection against a broad spectrum of viral strains. One proposed strategy is to utilize conserved viral protein, M2. Clinical trials of M2-containing influenza vaccines were recently initiated by US and European companies.
Features of replication suggest viruses have common themes, vulnerabilities
A study of the reproductive apparatus of a model virus is bolstering the idea that broad classes of viruses - including those that cause important human diseases such as AIDS, SARS and hepatitis C - have features in common that could eventually make them vulnerable to broad-spectrum antiviral agents.
'Insulator' helps silence genes in dormant herpes virus
By adulthood, most people have suffered at least one bout of painful cold sores brought on by the Herpes simplex virus 1, also known as HSV-1.
Finnish scientists discovered a new approach to treat virus-induced lymphomas
Kaposi's sarcoma herpesvirus (KSHV) is a human tumor virus and an etiological agent for Kaposi's sarcoma and primary effusion lymphoma (PEL).
More Viral Genes Current Events and Viral Genes News Articles
 |
Viral Vectors: Gene Therapy and Neuroscience Applications by Michael G. Kaplitt (Editor), Arthur D. Loewy (Editor) Genetic manipulation of the adult mammalian nervous system is one of the most exciting areas in contemporary neurobiology. The explosive growth of this field has been facilitated by harnessing the power of viruses to transfer genetic material into mammalian cells. Viral Vectors: Gene Therapy and Neuroscience Applications represents the first comprehensive review of viral vector applications to the nervous system by leaders in virology, molecular neurobiology, neuroanatomy, and developmental neurobiology. It serves both as a source of fundamental information for those newly interested in viral vectors and as a compilation of state-of-the-art technologies and applications for more experienced researchers. This work provides expert background information on viral systems, and the broad... |
 |
Gene-Eden: Antiviral Supplement, Natural, Broad Range, Scientifically Tested, Patented Formula by polyDNA The development of Gene-Eden was inspired by Dr. Hanan Polansky's highly acclaimed scientific discovery of the role of chronic viruses in chronic disease. To develop an effective formulation, the scientists at polyDNA scanned the scientific literature, analyzed thousands of papers using a unique bioinformatics-based computer program, and identified natural ingredients which are effective against many chronic viruses. The result is Gene-Eden, a natural broad range antiviral formulation that targets viruses during their chronic or latent phase. For full results, Gene-Eden needs to be taken for at least two months. At the lowest dose, a bottle provides 1-month supply of capsules. Therefore, we recommend starting with a minimum of two bottles. At the highest dose, we recommend starting... |
 |
Viral Vectors: Basic Science and Gene Therapy by Angel Cid-Arregui (Editor), Alejandro Garcia-Carranca (Editor) This major new volume provides in-depth descriptions of the most relevant viral vector systems currently in use and describes the recent important developments in this field. 37 chapters provide updated methods to prepare the vectors as well as information on their applications to cell biology, neurobiology, gene therapy and more. |
 |
Gene Delivery to Mammalian Cells: Volume 2: Viral Gene Transfer Techniques (Methods in Molecular Biology) by William C. Heiser (Editor) Details procedures for delivering genes into cells using viral vectors. DNLM: Cloning, Molecular. |
|
Viral Gene Expression Regulation by Eli B. Galos (Editor) Viral gene expression regulation refers to any of the processes by which cytoplasmic factors influence the differential control of gene action in viruses. The interplay of the viral genome with the host metabolic machinery involves modifications in both gene expression and regulation. Retroviruses have adapted themselves to use this machinery while maintaining the cell integrity, which is essential to preserve their survival. Consequently, there can be variable host pathogenicity associated with several diseases such as malignancies, immunodeficiencies, and neurological disorders. This book describes current research in the field, and gives a better understanding of the retroviral gene expression regulation that is essential to develop prevention and therapeutic strategies in the future. | |
|
Transformation and Regeneration of Groundnut, and Utilization of Viral Genes to Induce Resistance to Virus Diseases Summary and Recommendations of a Meeting 24-27 Apr. 1992 by International Crops Research Institute for the Semi-Arid Tropics (ICRISAT) (Publisher) | |
|
Transgene awarded European patent covering non-viral gene delivery technology.(Brief Article): An article from: BIOTECH Patent News by Biotech Patent News (Publisher) This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on June 1, 2000. The length of the article is 405 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Transgene awarded European patent covering non-viral gene delivery technology.(Brief Article) Publication: BIOTECH Patent News (Newsletter) Date: June 1, 2000 Publisher: Biotech Patent News Volume: 14 Issue: 6 Page: NA Article Type: Brief Article Distributed by Thomson... | |
 |
Non-viral Gene Therapy: Gene Design and Delivery by Kazunari Taira (Editor), Kazunori Kataoka (Editor), Takuro Niidome (Editor) The development of gene medicine based on the concept of molecular therapy has opened new medical horizons. Among the many techniques in gene medicine, gene design and delivery are especially significant in clinical applications. This book presents state-of-the-art information on non-viral gene-delivery techniques, covering a broad spectrum of disciplines that include chemistry, molecular biology, cell biology, and pharmacokinetics. Major sections introduce molecules for gene delivery and their properties; technologies of controlled gene delivery in vitro and in vivo; therapeutic genes and the status of clinical applications; and the design of genes based on current RNA technology, with revolutionary developments in the world of RNAi shown to be key factors in gene medicine. This... |
|
Expression of Eukaryotic Viral and Cellular Genes by R. Pettersson (Editor) | |
|
Cell Genesys issued patent for adeno-associated viral gene therapy.(Brief Article): An article from: BIOTECH Patent News by Biotech Patent News (Publisher) This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on May 1, 2000. The length of the article is 616 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Cell Genesys issued patent for adeno-associated viral gene therapy.(Brief Article) Publication: BIOTECH Patent News (Newsletter) Date: May 1, 2000 Publisher: Biotech Patent News Volume: 14 Issue: 5 Page: NA Article Type: Brief Article Distributed by Thomson... |
| © 2009 BrightSurf.com |